Navigation Links
University of Arizona research on scorpion antivenom published in NEJM
Date:5/13/2009

TUCSON, Ariz. --Youngsters suffering severe nerve poisoning following a scorpion sting recover completely and quickly if a scorpion-specific antivenom is administered, according to a study conducted by researchers from The University of Arizona and reported in the May 14 issue of The New England Journal of Medicine.

The article, "Antivenom for Critically Ill Children with Neurotoxicity from Scorpion Stings," recounts a study of 15 children conducted in Tucson, Ariz., during 2004 and 2005. All of the children had been admitted to a pediatric intensive care unit following a scorpion sting and were experiencing abnormal eye movements, uncontrolled thrashing of limbs and respiratory distress, all symptoms of nerve poisoning caused by the venom of the bark scorpion.

The principal investigator of the study and lead author of the article is Leslie Boyer, MD, director of the VIPER (Venom Immunochemistry, Pharmacology and Emergency Response) Institute at The University of Arizona College of Medicine and medical director of the Arizona Poison and Drug Information Center at the UA College of Pharmacy.

In the study, eight of the children, most of whom were under 6 years, received a scorpion antivenom that is commercially available in Mexico but is considered an investigational drug in the United States and is not approved for general use by the U.S. Food and Drug Administration. The seven other study participants received a placebo (a preparation containing no medication).

The symptoms of nerve poisoning were resolved in all of the children treated with the antivenom in less than four hours, and usually within two hours. The children who received the placebo continued to experience nerve poisoning for four hours or more and required large doses of sedative medication and extended hospitalization.

"This study told us that the dangerous effects of bark scorpion venom can be reversed quickly with the right antivenom," Dr. Boyer says. "One hundred percent of the children who received it got better very quickly, meaning that using this antivenom in the emergency room will make intensive care treatment unnecessary for most patients. This is particularly important in small Arizona towns without pediatric intensive care units. By avoiding helicopter trips and intensive care stays, we can save lives and keep treatment costs down at the same time."

Andreas Theodorou, MD, a professor of pediatrics and chief medical officer of University Medical Center in Tucson, was part of the study team.

"This antivenom basically takes symptoms away in a very short time," Dr. Theodorou says. "What was a life-threatening disease that would put kids in the pediatric ICU has become, for most of them, an outpatient disease."


'/>"/>

Contact: Ginny Geib
geib@pharmacy.arizona.edu
520-626-3389
University of Arizona, College of Pharmacy
Source:Eurekalert

Related medicine news :

1. Nordstrom Beat the Bridge to Beat Diabetes Run to Temporarily Suspend Traffic in University District on Sunday, May 17
2. Belmont University Graduate Launches Healthy Soul Food Restaurant on Nashvilles Historic Jefferson Street
3. University of Minnesota Physicians Chooses MedAptus Following Comprehensive Vendor Review
4. Ross University School of Medicine Expands Clinical Rotations on East Coast
5. Statement by Joseph A. Califano, Jr., Chairman and Founder, The National Center on Addiction and Substance Abuse at Columbia University and Former U.S. Secretary of Health, Education, and Welfare, on New Report by the National Association of Boards of Pha
6. University of Miami President Donna E. Shalala, Pennsylvania Gov. Edward G. Rendell: Nurse Practitioners Are Key to Obama Health Care Reform, Call for Increased Federal Funding for Innovative Nurse-Managed Health Care
7. University HealthSystem Consortium Selects Sodexo to Provide Food and Nutrition Services
8. Grand Canyon University Recognizes Nurses
9. Medical University of South Carolina Automates Grants Allocation Process with Lombardi Business Process Management Software
10. Ajou University Hospital Becomes First in Korea to Treat Using RapidArc(TM) Radiotherapy Technology from Varian Medical Systems
11. Davis Vision, Visionworks, United Concordia Dental and Louisiana State University School of Dentistry Partner with Hands on New Orleans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, ... Dallas, Miami, and Raleigh regions, is organizing an extended charity drive to benefit ... deadly chromosome abnormality. , After struggling since birth with several health challenges, T.J. ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) ... and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton ... until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of ...
(Date:10/13/2017)... N.Y (PRWEB) , ... October 13, 2017 , ... Lori ... became a member of ElderCounsel, a national organization of elder law and special needs ... changing laws and rules. It also provides a forum to network with elder law ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology: